These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 19395241)

  • 21. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients.
    Day JC; Wood G; Dewey M; Bentall RP
    Br J Psychiatry; 1995 May; 166(5):650-3. PubMed ID: 7620752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subjective assessments of the quality of life, well-being and self-efficacy in patients with schizophrenia.
    Chino B; Nemoto T; Fujii C; Mizuno M
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):521-8. PubMed ID: 19531107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rating of medication influences (ROMI) scale in schizophrenia.
    Weiden P; Rapkin B; Mott T; Zygmunt A; Goldman D; Horvitz-Lennon M; Frances A
    Schizophr Bull; 1994; 20(2):297-310. PubMed ID: 7916162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone.
    Westheide J; Cvetanovska G; Albrecht C; Bliesener N; Cooper-Mahkorn D; Creutz C; Hornung WP; Klingmüller D; Lemke MR; Maier W; Schubert M; Sträter B; Kühn KU
    J Sex Med; 2008 Dec; 5(12):2816-26. PubMed ID: 18466271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attitudes towards neuroleptic treatment: reliability and validity of the attitudes towards neuroleptic treatment (ANT) questionnaire.
    Kampman O; Lehtinen K; Lassila V; Leinonen E; Poutanen O; Koivisto A
    Schizophr Res; 2000 Oct; 45(3):223-34. PubMed ID: 11042440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance of the Italian version of the subjective well-being under neuroleptic (SWN) scale in schizophrenic outpatients.
    Balestrieri M; Giaroli G; Mazzi M; Bellantuono C
    Pharmacopsychiatry; 2006 May; 39(3):81-4. PubMed ID: 16721695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rating scales to measure side effects of antipsychotic medication: A systematic review.
    van Strien AM; Keijsers CJ; Derijks HJ; van Marum RJ
    J Psychopharmacol; 2015 Aug; 29(8):857-66. PubMed ID: 26156860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reliability and validity of the Medication Adherence Rating Scale in a cohort of patients with schizophrenia from Nigeria.
    Owie GO; Olotu SO; James BO
    Trends Psychiatry Psychother; 2018; 40(2):85-92. PubMed ID: 29768528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics.
    Watanabe A; Shibata I; Kato T
    Psychiatry Clin Neurosci; 2004 Jun; 58(3):268-73. PubMed ID: 15149292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement of antipsychotic-induced side effects: support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement.
    Lambert TJ; Cock N; Alcock SJ; Kelly DL; Conley RR
    Hum Psychopharmacol; 2003 Jul; 18(5):405-11. PubMed ID: 12858330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A large-scale validation study of the Medication Adherence Rating Scale (MARS).
    Fialko L; Garety PA; Kuipers E; Dunn G; Bebbington PE; Fowler D; Freeman D
    Schizophr Res; 2008 Mar; 100(1-3):53-9. PubMed ID: 18083007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of adherence to antipsychotics medication on the quality of life among patients with schizophrenia in Indonesia.
    Endriyani L; Chien CH; Huang XY; Chieh-Yu L
    Perspect Psychiatr Care; 2019 Apr; 55(2):147-152. PubMed ID: 29578605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs.
    Naber D; Moritz S; Lambert M; Pajonk FG; Holzbach R; Mass R; Andresen B
    Schizophr Res; 2001 May; 50(1-2):79-88. PubMed ID: 11378316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
    Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW
    Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset.
    Fond G; Boyer L; Boucekine M; Aden LA; Schürhoff F; Tessier A; Andrianarisoa M; Berna F; Brunel L; Capdevielle D; Chereau I; Mallet J; Denizot H; Dorey JM; Dubertret C; Dubreucq J; Faget C; Gabayet F; Rey R; Richieri R; Passerieux C; Schandrin A; Urbach M; Vidailhet P; Llorca PM; Misdrahi D;
    Schizophr Res; 2017 Apr; 182():84-89. PubMed ID: 27789187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study.
    Brain C; Allerby K; Sameby B; Quinlan P; Joas E; Karilampi U; Lindström E; Eberhard J; Burns T; Waern M
    Eur Neuropsychopharmacol; 2013 Dec; 23(12):1754-62. PubMed ID: 24091164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multisite investigation of the reliability of the Scale for the Assessment of Negative Symptoms.
    Mueser KT; Sayers SL; Schooler NR; Mance RM; Haas GL
    Am J Psychiatry; 1994 Oct; 151(10):1453-62. PubMed ID: 7916540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
    Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
    Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
    Kim EY; Kim SH; Lee NY; Jung DC; Kim YS; Ahn YM
    Pharmacopsychiatry; 2012 Mar; 45(2):57-63. PubMed ID: 22411694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.